A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease.
Identifieur interne : 001B12 ( Ncbi/Curation ); précédent : 001B11; suivant : 001B13A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease.
Auteurs : Carlos Singer [États-Unis] ; Janice Lamb ; Amanda Ellis ; Gary LaytonSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2007.
English descriptors
- KwdEn :
- Adult, Benzimidazoles (adverse effects), Benzimidazoles (therapeutic use), Demography, Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Double-Blind Method, Drug Administration Schedule, Drug Tolerance, Early Diagnosis, Female, Humans, Indoles (adverse effects), Indoles (therapeutic use), Male, Parkinson Disease (diagnosis), Parkinson Disease (drug therapy).
- MESH :
- chemical , adverse effects : Benzimidazoles, Dopamine Agonists, Indoles.
- chemical , therapeutic use : Benzimidazoles, Dopamine Agonists, Indoles.
- diagnosis : Parkinson Disease.
- drug therapy : Parkinson Disease.
- Adult, Demography, Double-Blind Method, Drug Administration Schedule, Drug Tolerance, Early Diagnosis, Female, Humans, Male.
Abstract
To assess the safety and efficacy of sumanirole, a highly selective dopamine agonist, versus placebo and demonstrate its noninferiority to ropinirole, 614 patients with early Parkinson's disease (PD) were treated with sumanirole, 1 to 16 mg/day; ropinirole, 0.75 to 24 mg/day; or placebo. Primary end point in this flexible-dose, double-blind, double-dummy, parallel-group study of 40 weeks was the change in total sum of the United Parkinson's Disease Rating Scale (UPDRS) Parts II + III scores from baseline to end of maintenance. Approximately half the subjects in the sumanirole and placebo groups withdrew early from the study, most (51.8% and 68.5%, respectively) due to lack of efficacy. Of the ropinirole subjects who withdrew (50.5%), most discontinued because of adverse events. In sumanirole and ropinirole groups, mean changes from baseline of -2.48 and -5.20 in UPDRS II + III mean scores were significant versus 0.38 in the placebo group (P
DOI: 10.1002/mds.21361
PubMed: 17318839
DOI: 10.1002/mds.21361
PubMed: 17318839
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002827
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002827
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002A18
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001B12
Links to Exploration step
pubmed:17318839Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease.</title><author><name sortKey="Singer, Carlos" sort="Singer, Carlos" uniqKey="Singer C" first="Carlos" last="Singer">Carlos Singer</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, University of Miami, Miami, Florida, USA. csinger@med.miami.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Miami, Miami, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Lamb, Janice" sort="Lamb, Janice" uniqKey="Lamb J" first="Janice" last="Lamb">Janice Lamb</name></author><author><name sortKey="Ellis, Amanda" sort="Ellis, Amanda" uniqKey="Ellis A" first="Amanda" last="Ellis">Amanda Ellis</name></author><author><name sortKey="Layton, Gary" sort="Layton, Gary" uniqKey="Layton G" first="Gary" last="Layton">Gary Layton</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="doi">10.1002/mds.21361</idno><idno type="RBID">pubmed:17318839</idno><idno type="pmid">17318839</idno><idno type="wicri:Area/PubMed/Corpus">002827</idno><idno type="wicri:Area/PubMed/Curation">002827</idno><idno type="wicri:Area/PubMed/Checkpoint">002A18</idno><idno type="wicri:Area/Ncbi/Merge">001B12</idno><idno type="wicri:Area/Ncbi/Curation">001B12</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease.</title><author><name sortKey="Singer, Carlos" sort="Singer, Carlos" uniqKey="Singer C" first="Carlos" last="Singer">Carlos Singer</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, University of Miami, Miami, Florida, USA. csinger@med.miami.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Miami, Miami, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Lamb, Janice" sort="Lamb, Janice" uniqKey="Lamb J" first="Janice" last="Lamb">Janice Lamb</name></author><author><name sortKey="Ellis, Amanda" sort="Ellis, Amanda" uniqKey="Ellis A" first="Amanda" last="Ellis">Amanda Ellis</name></author><author><name sortKey="Layton, Gary" sort="Layton, Gary" uniqKey="Layton G" first="Gary" last="Layton">Gary Layton</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Benzimidazoles (adverse effects)</term><term>Benzimidazoles (therapeutic use)</term><term>Demography</term><term>Dopamine Agonists (adverse effects)</term><term>Dopamine Agonists (therapeutic use)</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Drug Tolerance</term><term>Early Diagnosis</term><term>Female</term><term>Humans</term><term>Indoles (adverse effects)</term><term>Indoles (therapeutic use)</term><term>Male</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Benzimidazoles</term><term>Dopamine Agonists</term><term>Indoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Benzimidazoles</term><term>Dopamine Agonists</term><term>Indoles</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Demography</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Drug Tolerance</term><term>Early Diagnosis</term><term>Female</term><term>Humans</term><term>Male</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To assess the safety and efficacy of sumanirole, a highly selective dopamine agonist, versus placebo and demonstrate its noninferiority to ropinirole, 614 patients with early Parkinson's disease (PD) were treated with sumanirole, 1 to 16 mg/day; ropinirole, 0.75 to 24 mg/day; or placebo. Primary end point in this flexible-dose, double-blind, double-dummy, parallel-group study of 40 weeks was the change in total sum of the United Parkinson's Disease Rating Scale (UPDRS) Parts II + III scores from baseline to end of maintenance. Approximately half the subjects in the sumanirole and placebo groups withdrew early from the study, most (51.8% and 68.5%, respectively) due to lack of efficacy. Of the ropinirole subjects who withdrew (50.5%), most discontinued because of adverse events. In sumanirole and ropinirole groups, mean changes from baseline of -2.48 and -5.20 in UPDRS II + III mean scores were significant versus 0.38 in the placebo group (P </div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B12 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001B12 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:17318839
|texte= A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:17318839" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |